Scios merger talks
Executive Summary
Scios is in discussions with a "number of life sciences companies concerning potential strategic transactions," the company said in response to reports it is in merger talks with Johnson & Johnson. The transactions under discussion include a merger deal and partnership for Scios' rheumatoid arthritis oral p38 MAP kinase inhibitor program (Phase II SCIO-469 and Phase I SCIO-323). Scios has been previously touted as an acquisition target, given the success of the congestive heart failure drug Natrecor. J&J's recent acquisitions include Alza (2001) and Centocor (1999)...
You may also be interested in...
J&J Buys Scios: Will Natrecor Make Another Centocor?
Johnson & Johnson will gain access to Scios' Phase II oral rheumatoid arthritis program through its proposed $2.4 bil. acquisition of the biotech company
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.